Here are relevant reports on : inflammatory-disease-therapeutics-market
-
Poultry Medicine/Pharmaceuticals Market by Animal Type (Chickens, Turkeys, Ducks), Product (Drugs, Vaccines, Feed Additives), Disease Indication (Newcastle disease, Infectious Bursal Disease, Salmonella), Route of Administration - Global Forecast to 2029
The global poultry medicine/pharmaceuticals market, valued at US$4.73 billion in 2023, stood at US$5.01 billion in 2024 and is projected to advance at a resilient CAGR of 5.9% from 2024 to 2029, culminating in a forecasted valuation of US$6.68 billion by the end of the period. The growth of the poultry medicine/pharmaceutical industry can be attributed to the rising global population and consumption of poultry meat and eggs leading to more poultry farming practiced notably in the developing regions where poultry is the cheapest source of protein.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – (Pipeline Forecast & Market Forecast in G8 Countries) (2011 – 2020)
The incidence of acute lymphocytic leukemia is high in children from 0 to 14 years than the people aged above 14. It is the most common childhood acute lymphocytic leukemia. However, the acute lymphocytic leukemia may also occur in adults. Acute lymphocytic leukemia distribution depends on age. For instance, 30% of is diagnosed before the age of 5 and 55% of ALL age 15.The acute lymphocytic leukemia market is segmented into two types; namely childhood acute lymphocytic leukemia, and adult acute lymphocytic leukemia. The market was dominated by Hyper-CVAD regimen in 2010. However, in 2020, the market is expected to be equally dominated by Hyper-CVAD and Linker regimen.
- Published: December 2013
- Price: $ 4950
- TOC Available:
-
Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Chronic lymphocytic leukemia is the second most common cancer in adult males and rarely occurs in children. The risk of chronic lymphocytic leukemia is closely associated with age. About 90% of chronic lymphocytic leukemia is diagnosed in middle age. Incidence rate of CLL is high in men and women over 50 years of age. The chronic lymphocytic leukemia market is segmented into two types; namely childhood chronic lymphocytic leukemia and adulthood lymphocytic leukemia. The market was dominated by Campath drug in 2010. However, in 2020, the market is expected to be equally dominated by GA101/RG7159 molecule and Arzerra drug.
- Published: December 2011
- Price: $ 4950
- TOC Available:
-
RNAI Technology Market- by Application (Research, Therapeutics) - Global Forecasts to 2019
The report presents the latest advances in RNAi technologies and their clinical implication as a therapeutic platform. It charts the current trends in RNAi therapeutics, and analyzes the opportunities and challenges faced by the RNAi companies. The focus will be on the clinical needs, patented technologies and the competitive landscape across geographies.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Prostate Cancer Therapeutics Market (2010-2020) (Opportunity Analysis, Pipeline Assessment and Global Market Forecast)
Prostate cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer-related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Lung Cancer Therapeutics Market (NSCLC & SCLC) - 2010-2020 (Pipeline Assessment and Market Forecast) in G7 countries
Lung cancer is responsible for most of the deaths (due to cancer) across the globe. With just one drug slated to be launched by 2014 – Talactoferrin by Agennix AG, for patients with advanced lung cancer; having failed both chemotherapy and treatments with epidermal growth factor receptor (EFGR) - Tyrosine kinase inhibitor (TKI). Lung cancer is still an area with high unmet need for early diagnosis and limited treatment options in the advanced stages of lung cancer.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. Incidence rate of acute myeloid leukemia is high in men and women over 50 years. The acute myeloid leukemia market is segmented into two types; namely childhood acute myeloid leukemia and adulthood acute myeloid leukemia. The market was dominated by AVD regimen in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, Cyatarabine, and Quizartinib drug.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Global Nanomedical Devices and Therapeutics Market (2011-2016)
Nanomedicine, an application of nanotechnology in medical science, is an evolving market. It represents an important segment of nanotechnology which will significantly change the course of treating life threatening diseases. This, unlike other treatment options, is significantly expected to enhance efficacy and minimize overall adversities. Toxicity and environmental impact of nanoscale materials are the major problems nanomedicine. Research and development in nanomedicine is expected to offer a pool of novel products which will improve the health of patients. The robust product pipeline for nanobiomaterials poses a health picture of the market creates significant growth opportunities. However these will have to go through stringent testing protocols before commercialization.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Inflammatory, Autoimmune, Cardiovascular) & Region - Global Forecast to 2028
The global stem cell therapy market, valued at US$259 million in 2022, stood at US$286 million in 2023 and is projected to advance at a resilient CAGR of 16.5% from 2023 to 2028, culminating in a forecasted valuation of US$615 million by the end of the period. Market growth is driven mainly by factors such as rise in funding for stem cell research, upsurge in the number of cell therapy production facilities that have GMP certification, and increased in the number of clinical trials associated with stem cell therapies.
- Published: December 2023
- Price: $ 4950
- TOC Available:
-
Veterinary API Market by API Type (Antimicrobials (Fluoroquinolones, Tetracyclines), Vaccines, Hormones, Antimicrobials, Anti-inflammatory, Hormones), Synthesis Type, Route of Administration, and Animal Type - Global Forecast to 2028
The global veterinary API market, valued at US$8.0 billion in 2022, stood at US$8.5 billion in 2023 and is projected to advance at a resilient CAGR of 6.9% from 2023 to 2028, culminating in a forecasted valuation of US$11.9 billion by the end of the period. The veterinary active pharmaceutical ingredient (API) market is growing due to various factors, including the increased occurrence of transboundary and zoonotic diseases, a rise in the global animal population and pet ownership, and the implementation of improved disease control and prevention measures.
- Published: June 2023
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
